The invention of IV Busulfex™ (the intravenous formulation of
busulfan) has contributed to a dramatic change in the standard of care
for patients undergoing stem cell transplantation for leukemia. It
also has greatly improved the outlook for patients with hematologic
(blood) and lymphoid cancers.
In March, the lead
inventor, Borje S. Andersson, M.D., Ph.D., professor in MD Anderson's
Department of Stem Cell Transplantation...